VMP using weekly and subcutaneous bortezomib is well tolerated and efficacious for newly diagnosed and relapsed myeloma patients

被引：0
|
作者：
O'Sullivan, J. M. [1 ]
Kumar, S. [1 ]
Yeomans, C. [1 ]
Milner, G. [1 ]
Schey, S. [1 ]
Kazmi, M. [1 ]
Streetly, M. J. [1 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
154
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [1] Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma
    Ong, Shin-Yeu
    Ng, Hong Yen
    Surendran, Shilpa
    Linn, Yeh Ching
    Chen, YunXin
    Goh, Yeow Tee
    Diong, Colin
    Gopalakrishnan, Sathish Kumar
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 754 - 756
  • [2] Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma
    Suvannasankha, Attaya
    Smith, Gina G.
    Juliar, Beth E.
    Abonour, Rafat
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02): : 131 - 134
  • [3] Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
    Moore, Sally
    Atwal, Sangeeta
    Sachchithanantham, Sajitha
    Streetly, Matthew
    Khan, Iftekhar
    Percy, Laura
    Narat, Santosh
    D'Sa, Shirley
    Rabin, Neil
    Johnston, Rosalynd
    Schey, Steve
    Yong, Kwee
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (05) : 420 - 425
  • [4] Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
    Ashrafi, Farzaneh
    Moghaddas, Azadeh
    Darakhshandeh, Ali
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (01) : 56 - 59
  • [5] BORTEZOMIB BY SUBCUTANEOUS WAY PLUS MELFALAN AND PREDNISONE (VMP) IN PATIENTS WITH MULTIPLE MYELOMA OF NEWLY DIAGNOSED NON CANDIDATES TO TRASPLANTATION: EXPERIENCE IN SPAIN
    De Arriba De La Fuente, F.
    Vidal Rivas, S.
    Duran, S.
    Alvarez Miguel, A.
    Lopez San Roman, I
    Dios Loureiro, A. M.
    Rios Tamayo, R.
    Gonzalez, M. S.
    Prieto Pareja, E.
    Garcia Sanchez, R.
    Barez, A.
    Escalante, F.
    Clavero, C.
    Tejedor, A.
    Capote, F. J.
    Cabanas, V
    Ballesteros Andres, M.
    Couto, C.
    Zamidio, G.
    Mateos Manteca, M., V
    HAEMATOLOGICA, 2015, 100 : 102 - 102
  • [6] Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients
    Herbaux, Charles
    Joao, Cristina M.
    Plocque, Alexia
    Richez, Valentine
    Gay, Francesca
    Renaud, Loic
    Legros, Laurence
    Garderet, Laurent
    Ikhlef, Souhila
    Pegourie, Brigitte
    Escoffre-Barbe, Martine
    Royer, Bruno
    Voillat, Laurent
    Hulin, Cyrille
    Banos, Anne
    Voog, Eric G.
    Karlin, Lionel
    Stoppa, Anne-Marie
    Benboubker, Lotfi
    Zweegman, Sonja
    De Jongh, Eva
    Abildgaard, Niels
    Le Du, Katell
    Jurczyszyn, Artur J.
    Moreau, Philippe
    Facon, Thierry
    Caillot, Denis
    Terpos, Evangelos
    Leleu, Xavier
    BLOOD, 2014, 124 (21)
  • [7] EFFICACY AND SAFETY OF WEEKLY INFUSION BORTEZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Bringhen, S.
    Genuardi, M.
    Rossi, D.
    Petrucci, M.
    Andriani, A.
    Rizzi, R.
    Mele, G.
    Aitoro, G.
    Mettivier, V.
    Annibali, O.
    Rossini, F.
    Gentilini, P.
    Pavone, V.
    Cellini, C.
    Giuliani, N.
    Rauco, A.
    Baraldi, A.
    Dominietto, A.
    Capaldi, A.
    Pescosta, N.
    Rizzi, R.
    Nozza, A.
    Spadano, A.
    De Stefano, V.
    Holanek, M.
    Gaidano, G.
    Boccadoro, M.
    Palumbo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 149 - 149
  • [8] Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
    de Arriba de la Fuente, Felipe
    Soledad Duran, Maria
    Angel Alvarez, Miguel
    Lopez Sanroman, Isabel
    Maria Dios, Ana
    Rios Tamayo, Rafael
    Garcia, Ricarda
    Sonia Gonzalez, Marta
    Prieto, Elena
    Barez, Abelardo
    Escalante, Fernando
    Tejedor, Aurelia
    Ballesteros, Monica
    Cabanas, Valentin
    Javier Capote, Francisco
    Couto, Carmen
    Garzon, Sebastian
    Gonzalez-Pardo, Miriam
    Mateos Manteca, Maria Victoria
    SEMINARS IN HEMATOLOGY, 2018, 55 (04) : 189 - 196
  • [9] COMPARATIVE EFFICACY OF SUBCUTANEOUS AND INTRAVENOUS ADMINISTRATION OF BORTEZOMIB IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Skvortsova, N.
    Pospelova, T.
    Kovynev, I.
    Nechunaeva, I.
    HAEMATOLOGICA, 2014, 99 : 657 - 657
  • [10] Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS
    Fu, Weijun
    Huang, Honghui
    Li, Wei
    An, Gang
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, Chor Sang
    Qi, Ming
    Wang, Jianping
    Song, Yang
    Jia, Bin
    Yang, Xue
    Liu, Wenyu
    Li, Yunan
    Zhang, Renyi
    Hou, Jian
    Wang, Jianxiang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S125 - S125
12345